Triazolopyrimidine compounds and uses thereof

Abstract

wherein R1, R2, R3, R4, R5, and n are as defined herein.

1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
    is a single bond or a double bond; 
 R 1  and R 2  are independently H or halogen; 
 R 3  is independently selected from: halogen, phenyl, and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A ; 
 each R 3A  is independently selected from: halogen, CN, —(O) m —(C 1 -C 6  alkyl substituted with 0-1 R 3B ), C 1 -C 6  haloalkyl, C 1 -C 6  haloalkoxy, R 3C , —OR 3C , —C(═O)R 3D , NR 3E R 3F , —C(═O)NR 3E R 3F , —NHC(═O)R 3D , —S(═O) 2 R 3D , —S(═O) 2 NR 3E R 3F , —NHS(═O) 2 (C 1 -C 4  alkyl), and —CR 3C R 3E R 3G ; 
 R 3B  is independently selected from: OH, NR e R f , C 1 -C 4  alkoxy, —C(═O)NR e R f , —S(═O) 2 (C 1 -C 4  alkyl), —NHC(═O)(C 1 -C 4  alkyl), and a 5- to 6-membered heterocycloalkyl comprising carbon atoms and 1-2 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said heterocycloalkyl is substituted with 0-2 R c ; 
 each R 3C  is independently selected from: C 3 -C 6  cycloalkyl, phenyl, and a 4- to 7-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein each moiety is substituted with 0-2 R c ; 
 each R 3D  is independently selected from: C 1 -C 4  alkyl and R 3C ; 
 R 3E  and R 3G  are, at each occurrence, independently selected from: H and C 1 -C 4  alkyl; 
 each R 3F  is independently selected from: H and C 1 -C 4  alkyl substituted with 0-1 R d ; 
 R 4  is independently selected from: H, halogen and C 1 -C 4  alkyl; 
 R 5  is independently selected from OH and C 1 -C 4  alkyl; 
 each R a  is independently selected from: H, →O, C 1 -C 4  alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4  alkyl), —CO 2 (C 1 -C 4  alkyl), C 3 -C 6  cycloalkyl, and benzyl; 
 R b  is independently selected from: halogen, OH and C 1 -C 4  alkoxy; 
 each R c  is independently selected from: ═O, halogen, OH, C 1 -C 4  alkyl, C 1 -C 4  haloalkyl, C 1 -C 4  alkoxy, and C 1 -C 4  haloalkoxy; 
 R d  is independently selected from: OH and NR e R f ; 
 R e  and R f  are, at each occurrence, independently selected from: H and C 1 -C 4  alkyl; 
 each p is independently selected from 0, 1 and 2; and 
 m and n are, at each occurrence, independently selected from 0 and 1. 
 
     
     
         2 . The compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , wherein:
 each R 3A  is independently selected from: halogen, CN, —(O) m —(C 1 -C 4  alkyl substituted with 0-1 R 3B ), C 1 -C 4  haloalkyl, C 1 -C 4  haloalkoxy, R 3C , —C(═O)R 3D , NR 3E R 3F , —C(═O)NR 3E R 3F , —S(═O) 2 R 3D , —S(═O) 2 NHR 3F , —NHS(═O) 2 (C 1 -C 4  alkyl), —O—C 3 -C 6  cycloalkyl, and   
       
         
           
           
               
               
           
         
         R a  is independently selected from: H, →O, C 1 -C 4  alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4  alkyl), —CO 2 (C 1 -C 4  alkyl), and C 3 -C 6  cycloalkyl; 
         R 4  is H; 
         m is independently selected from 0 and 1; and 
         n is 0. 
       
     
     
         3 . The compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , wherein:
 R 1  is independently H or F;   R 2  is H; and   R 3  is independently selected from: phenyl, and a 6-membered heteroaryl comprising carbon atoms and 1-2 heteroatoms selected from N and NR a ; wherein said phenyl and heteroaryl are substituted with 0-3 R 3A .   
     
     
         4 . The compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , wherein:
 R 3  is independently selected from: phenyl, pyridyl, pyrimidyl, pyridazinyl and pyrazinyl; wherein each moiety is substituted with 0-3 R 3A .   
     
     
         5 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein:
 R 3  is independently selected from:   
       
         
           
           
               
               
           
         
       
     
     
         6 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein:
 R 3  is independently selected from:   
       
         
           
           
               
               
           
         
         each R 3A  is independently selected from: halogen, CN, —(O) m —(C 1 -C 4  alkyl substituted with 0-1 R 3B ), C 1 -C 4  haloalkyl, C 1 -C 4  haloalkoxy, —C(═O)NH 2 , —C(═O)NH(C 1 -C 4  alkyl), —C(═O)N(C 1 -C 4  alkyl) 2 , —C(═O)N(C 1 -C 4  alkyl)(CH 2 ) 2 N(C 1 -C 4  alkyl) 2 , —CH 2 NHC(═O)(C 1 -C 4  alkyl), —S(═O) 2 R 3D , —S(═O) 2 NH(C 1 -C 4  alkyl substituted with 0-1 OH), —NHS(═O) 2 (C 1 -C 4  alkyl), NH 2 , —NH(C 1 -C 4  alkyl), —N(C 1 -C 4  alkyl) 2 , C 3 -C 6  cycloalkyl, 
       
       
         
           
           
               
               
           
         
         R 3B  is independently selected from: OH, NH 2 , NH(C 1 -C 4  alkyl), N(C 1 -C 4  alkyl) 2 , C 1 -C 4  alkoxy, —C(═O)N(C 1 -C 4  alkyl) 2 , —S(═O) 2 (C 1 -C 4  alkyl), 
       
       
         
           
           
               
               
           
         
         R 3D  is independently selected from: C 1 -C 4  alkyl and 1H-piperidin-4-yl; and 
         each R a  is independently selected from: H, C 1 -C 4  alkyl, —C(═O)H, —C(═O)(C 1 -C 4  alkyl), and —CO 2 (C 1 -C 4  alkyl). 
       
     
     
         7 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein:
 R 3  is independently selected from:   
       
         
           
           
               
               
           
         
         each R 3A  is independently selected from: halogen, CN, —(O) m —(C 1 -C 4  alkyl substituted with 0-1 R 3B ), C 1 -C 4  haloalkyl, C 1 -C 4  haloalkoxy, —C(═O)NH 2 , —C(═O)NH(C 1 -C 4  alkyl), —C(═O)N(C 1 -C 4  alkyl) 2 , —C(═O)N(C 1 -C 4  alkyl)(CH 2 ) 2 N(C 1 -C 4  alkyl) 2 , —CH 2 NHC(═O)(C 1 -C 4  alkyl), —S(═O) 2 (C 1 -C 4  alkyl), NH 2 , NH(C 1 -C 4  alkyl), N(C 1 -C 4  alkyl) 2 , C 3 -C 6  cycloalkyl, 
       
       
         
           
           
               
               
           
         
         R 3B  is independently selected from: OH, N(C 1 -C 4  alkyl) 2 , C 1 -C 4  alkoxy, —C(═O)N(C 1 -C 4  alkyl) 2 , —S(═O) 2 (C 1 -C 4  alkyl), 
       
       
         
           
           
               
               
           
         
       
       and
 each R a  is independently selected from: H, C 1 -C 4  alkyl, —C(═O)H, —C(═O)(C 1 -C 4  alkyl), and —CO 2 (C 1 -C 4  alkyl). 
 
     
     
         8 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein:
 each R 3A  is independently selected from: F, Cl, CH 3 , —CH 2 OH, CH 2 F, CHF 2 , CF 3 , CN, —OCH 3 , —OCH 2 CH 3 , —OCH(CH 3 ) 2 , —OCHF 2 , —C(═O)N(CH 3 ) 2 , —CH 2 NHC(═O)CH 3 , —S(═O) 2 CH 3 , NH 2 , cyclopropyl,   
       
         
           
           
               
               
           
         
       
     
     
         9 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein said compound is of Formula (IA-1): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, wherein:
 R 1  is independently H or F; and 
 R 3A  is independently selected from: F, CH 3 , —CH 2 OH, CH 2 F, CHF 2 , CF 3 , and —OCH 3 . 
 
     
     
         10 . The compound according to  claim 1 , wherein:
 R 1  is independently H or F;   R 2  is H;   R 3  is independently a 5-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR a , O, and S(O) p ; wherein said heteroaryl is substituted with 0-3 R 3A ; and   R a  is independently selected from: H, C 1 -C 4  alkyl substituted with 0-1 R b , —C(═O)H, —C(═O)(C 1 -C 4  alkyl), —CO 2 (C 1 -C 4  alkyl), C 3 -C 6  cycloalkyl, and benzyl.   
     
     
         11 . The compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , wherein:
 R 3  is independently selected from:   
       
         
           
           
               
               
           
         
       
     
     
         12 . The compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 , wherein:
 R 1  is F.   
     
     
         13 . The compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , wherein said compound is selected from Examples 1 to 245. 
     
     
         14 . The compound according to  claim 1 , wherein said compound is selected from: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         15 . A pharmaceutical composition, comprising one or more pharmaceutically acceptable carriers and a compound or a pharmaceutically acceptable salt thereof, according to any one of  claim 1 . 
     
     
         16 . The pharmaceutical composition of  claim 15  further comprising at least one additional therapeutic agent. 
     
     
         17 . The pharmaceutical composition of  claim 16  where said at least one additional therapeutic agent is selected from other anti-cancer agents, immunomodulators, anti-allergic agents, anti-emetics, pain relievers, cytoprotective agents, and combinations thereof. 
     
     
         18 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , for use in therapy. 
     
     
         19 . Use of a compound or a pharmaceutically acceptable salt thereof, according to  claim 1 , in the manufacture of a medicament for treating a disease or disorder mediated by mediated by EED and/or PRC2. 
     
     
         20 . The use of  claim 19 , wherein said disease or disorder is selected from diffused large B cell lymphoma, follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas.